Clinical Trial Update: Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS [Phase 1]

View source ↗

Summary

The document reports completion of a Phase 1 safety study of GC1008 (fresolimumab) in patients with treatment-resistant idiopathic focal segmental glomeruloscle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Fresolimumab (Fresolimumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Focal Segmental Glomerulosclerosis | Phase 1 | Status: COMPLETED